Table 1.
Controls | Stable MCI | Prodromal AD | MCI-other | |
---|---|---|---|---|
Females/males | 27/11 | 39/36 | 40/18e, d | 10/16a |
Age, years | 77 ± 8 | 69 ± 7b | 76 ± 7c e | 73 ± 7c |
Carrier of APOE ε4 | 10 (26) | 33 (44) | 44 (76)b, d, e | 12 (46) |
MMSE score at baseline | 28.3 ± 1.8 | 28.2 ± 1.3 | 26.1 ± 1.6b, d, e | 27.0 ± 1.9a, c |
CSF P-tau, ng/ml | 31 ± 17 | 30 ± 15 | 52 ± 22b, d, f | 30 ± 12 |
CSF tau, ng/ml | 91 ± 49 | 80 ± 48 | 141 ± 68b, d, f | 80 ± 38 |
CSF Aβ, ng/ml | 265 ± 74 | 252 ± 61 | 154 ± 55b, d, f | 226 ± 77 |
Left frontal WMLs | 0.34 ± 0.63 | 0.36 ± 0.63 | 0.62 ± 0.77c | 0.96 ± 1.1a, c |
Right frontal WMLs | 0.29 ± 0.52 | 0.39 ± 0.72 | 0.59 ± 0.75 | 0.96 ± 1.1a, c |
Left parietal WMLs | 0.21 ± 0.62 | 0.31 ± 0.66 | 0.53 ± 0.75a, c | 0.88 ± 1.2a, c |
Right parietal WMLs | 0.32 ± 0.62 | 0.29 ± 0.63 | 0.59 ± 0.82c | 0.96 ± 1.1a, d |
Sum frontal WMLs | 0.63 ± 1.2 | 0.75 ± 1.3 | 1.2 ± 1.5 | 1.9 ± 2.1a, c |
Sum parietal WMLs | 0.53 ± 1.2 | 0.6 ± 1.3 | 1.1 ± 1.5a, c | 1.8 ± 2.3a, c |
Total sum frontoparietal WMLs | 1.2 ± 2.0 | 1.3 ± 2.4 | 2.3 ± 2.7a, c | 3.8 ± 4.0a, c |
Left basal ganglia infarcts | 0.08 ± 0.27 | 0.16 ± 0.37 | 0.17 ± 0.48e | 0.58 ± 0.81b, c |
Right basal ganglia infarcts | 0.05 ± 0.23 | 0.18 ± 0.51 | 0.26 ± 0.58 | 0.19 ± 0.40 |
Sum basal ganglia infarcts | 0.13 ± 0.34 | 0.34 ± 0.73 | 0.45 ± 0.88e | 0.77 ± 0.95a, c |
Total sum WMLs (including BG) | 1.3 ± 2.0 | 1.6 ± 2.7 | 2.8 ± 3.0a, d | 4.5 ± 4.4a, d |
Data are means ± SD or number (%). Stable MCI = MCI patients with stable cognitive functions during a follow-up period of 3.0 – 9.6 years; prodromal AD = MCI patients who developed AD during follow-up; WML = white matter lesions in subcortical brain matter; BG = basal ganglia.
p < 0.05
p < 0.005 vs. controls
p < 0.05
p < 0.005 stable MCI
p < 0.05,
p < 0.005 vs. MCI-other. Correction for multiple analyses has not been performed.